Introduction of Votumumab

Colorectal cancer (CRC) remains one of the most prevalent and lethal cancers in the world. Rapid and precise diagnosis is the key to increasing survival rates and directing appropriate treatment. Votumumab, a human monoclonal antibody containing the radioactive isotope technetium-99m ([99mTc]), contributes to this diagnostic process. Votumumab itself is not used for therapy, but it's invaluable for the diagnosis of colorectal cancer. As it targets the CTAA16.88 antigen, which is hyper-expressed on colon cancer cells, votumumab helps physicians identify cancer—particularly if it has returned or spread. Using the force of single-photon emission computed tomography (SPECT), this radiopharmaceutical can boost image resolution and give a clearer, more precise picture of tumor locations and disease pathology. Creative Biolabs, with its vast experience in molecular diagnostics, has invested in developing and deploying powerful tools such as votumumab to empower clinicians to make better, more informed decisions.

The Mechanism of Action of Votumumab

Knowing CTAA16.88: The Target of Votumumab

CTAA16.88 is a tumor antigen—a protein that is present in high amounts on the surface of colon cancer cells. This antigen is a complex of keratin polypeptides and has a molecular mass of 35–40 kDa. It's a major marker for colorectal cancer, making it a perfect candidate for votumumab. Votumumab binds specifically to CTAA16.88, making it possible to see cancers in the colorectal tract at their location when they are small and hard to see on standard imaging. Not only is CTAA16.88 crucial for identifying cancer cells, but it also tracks disease progression. It can be a predictor of recurrence or spread of the tumor, providing valuable insights into care for patients.

The role of CTAA16.88 is more than just a biomarker. It can be used in clinical practice to detect colorectal cancer early, particularly when other forms of imaging are inadequate. For instance, patients with elevated CEA but negative CT scans can still be correctly diagnosed using votumumab. Through binding to CTAA16.88, votumumab can reveal unseen diseases that may otherwise remain unrecognized. Moreover, it's hard to undervalue the antigen's role in tracking the performance of cancer therapies. By monitoring changes in the expression of CTAA16.88, doctors can tell if a therapy is working or if the cancer is beginning to spread.

How Votumumab Works?

• Votumumab Targets CRC Cells

Votumumab is diagnostically successful because it specifically binds to the CTAA16.88 antigen that is present on the surface of colorectal cancer cells. Votumumab is an IgG3-kappa-type monoclonal antibody that recognizes and binds to a specific region, or epitope, of the CTAA16.88 complex. This high specificity ensures votumumab can target only cancer cells of the colon, leaving healthy tissue undisturbed and normal cells easy to distinguish from cancerous ones.

Figure 1. The Mechanism of Action of Votumumab. (Creative Biolabs Original)

• Imaging with Votumumab: A Better View of Cancer

When injected into a patient, votumumab travels throughout the bloodstream, targeting tumor cells that bear the CTAA16.88 antigen. The antibody, now radiolabeled with technetium-99m, attaches to these cancer cells and begins to spew gamma rays. Such rays are detected by SPECT imaging, which produces precise, 3D reconstructions of the interior of the body. As votumumab accumulates in cancer growth sites, physicians can pinpoint tumor locations more accurately. SPECT images produced by this process offer a detailed picture of cancer's progression, enabling physicians to identify which tumors can be removed surgically and which may require more intense treatments, such as chemotherapy or radiation.

• Minimizing Staging Mistakes: Votumumab's Major Benefit

Perhaps the biggest advantage of votumumab-based imaging is minimizing mistakes in cancer staging. Classic scans such as CT scans sometimes understate cancer, either by failing to detect small tumours (understaging) or by overestimating the disease volume (overstaging). As a much more precise treatment, votumumab gives a more realistic picture of the true disease. Researchers have shown that votumumab imaging cuts overstaging from 26% (CT) to 4% and understaging from 41% to 27%. These accuracy gains are essential as they enable physicians to make better judgments about whether a patient needs surgery, chemotherapy, or other treatment. Staging errors can be minimized so that treatment can be more closely aligned to the patient's actual state.

• Detecting Hidden Disease

Another key feature of votumumab is the fact that it will find "occult" disease—a type of cancer not present on traditional scans. This is particularly critical when a patient exhibits elevated CEA but traditional CT scans show no abnormalities. In such cases, votumumab has been found to detect concealed disease in around 68% of patients. And in revealing these hidden tumors, votumumab saves us from a missed diagnosis by ensuring timely and accurate interventions.

Clinical Applications of Votumumab

Votumumab's capacity to deliver precise, high-resolution images directs treatment choices. The correct staging and detection of colorectal cancer also allows physicians to determine whether surgery can resect the cancer or if other therapies, such as chemotherapy, radiation, or targeted therapy, are needed. Votumumab scans, for instance, can identify whether tumors have expanded beyond their original location, indicating that metastases could determine whether or not to embark on more aggressive treatment. Votumumab imaging is estimated to affect treatment decisions in around a quarter of patients, enabling clinicians to make better choices based on an improved insight into the extent of the cancer.

Personalized medicine is central to modern oncology, and votumumab is an advance in that direction. By offering image-specific imaging that can pinpoint the precise position and size of tumors, votumumab enables clinicians to adapt treatment plans to each patient's individual disease history. It makes for better treatments and better patient outcomes.

What We Provide

For research use only. Not intended for any clinical use.